However, CCL2 plasma levels during long-term IFN treatment of MS patients did not predict therapeutic response at 1 or 2 years of therapy, thus questioning the relevance of CCL2 induction as a main mediator of the therapeutic action of IFN [122]. The gene discussed is IFNA1; the disease is myeloid sarcoma.